logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produswest2
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produswest2
Conference Material
|Abstract

Determining whether mass vaccination campaigns with fractional dose of PCV10 (Pneumosil®) could accelerate herd protection against pneumococcal transmission in sub-Saharan Africa

Soumana I
Download

Similar Content
Loading...
Loading...
Loading...
Abstract

BACKGROUND

In settings with low Pneumoccocal Conjugate Vaccine (PCV) coverage, mass campaigns targeting multi-age cohorts (MAC) might accelerate herd protection but ould be costly. Campaigns using fractional dose PCV would decrease cost and increase access.


METHODS

We conducted a cluster-randomized trial in Niger to evaluate the effect of a mass campaign targeting children aged 1-9 years on pneumococcal carriage. 63 villages were randomized in a 3:3:1 ratio to receive campaigns with a single full dose of a 10-valent PCV (Pneumosil®), a single 1/5th fractional dose, or no campaign. We conducted two independent carriage surveys among a total of 2268 households 6 months before and 6 months after vaccination, collecting a nasopharyngeal swab from a child aged 1-9 years for culture and serotyping. If the full-dose campaign was shown superior to control in carriage reduction, the non-inferiority of fractional-dose campaign was to be evaluated, with the lower bound of the 95%CI > -7.5%. Registration: NCT05175014, PACTR20211257448484


RESULTS

Surveys were conducted between December 22, 2021, and 18 March, 2022, and December 12, 2022, and March 9, 2023. The vaccination campaign was June 15-August 2, 2022. Participant characteristics were similar between the two surveys and across arms. Pre-vaccination, vaccine-type (VT) carriage was 15.6% in the full-dose arm, 17.9% in the fractional dose arm, and 18.8% in the control arm. Post-

vaccination, VT carriage was 4.6% in the full-dose arm, 8.0% in the fractional dose arm, and 16.5% in the control arm. In the primary analysis, the risk difference between the full dose and the control arms was -12.0% [-19.0; -5.0], p=0.001, and between the full dose and fractional dose arms it was -3.5% [-5.8; -1.1], meeting the prespecified non-inferiority criterion. Similar results were seen after adjustment for age, vaccine coverage and other factors.


CONCLUSION

MAC campaigns had a marked impact on VT carriage and fractional-dose campaigns met non-inferiority criteria. Such campaigns should be considered in low-coverage settings, including humanitarian emergencies, to accelerate population protection.

Countries

Niger

Subject Area

vaccinationpneumonia

Languages

English
Published Date
23 May 2024
Conference
Epicentre Scientific Day 2024
Determining whether mass vaccination campaigns with fractional dose of PCV10 (Pneumosil®) could accelerate herd protection against pneumococcal transmission in sub-Saharan Africa | Conference Material / Abstract | MSF Science Portal